The offering is a binary event for CLRO — without it, the Cortigent merger fails and the shell likely winds down. Even if funded, the combined entity faces years of cash burn with no near-term revenue catalyst. The 93%+ resale registration overhang will pressure the stock. Monitor for completion of the minimum $10M raise and Nasdaq listing approval for the combined company.
Executive Summary
ClearOne (CLRO) files Amendment No. 1 to its S-1 registration statement for a best-efforts unit offering to raise $10M-$15M, concurrent with a planned reverse-merger acquisition of pre-revenue neurotechnology company Cortigent. The offering is critical to fund the merger and Cortigent's clinical development pipeline (Orion visual cortical prosthesis, stroke recovery system), but the combined entity has no current revenue, a history of operating losses, and a going-concern qualification. The filing also registers 2.5M shares for resale by selling stockholders, representing 93% of current outstanding shares, creating significant overhang risk.
Key Financial Metrics
Key Facts
- Best-efforts offering of 2.86M-4.29M units at $3.50/unit, each consisting of one share of CLRO common stock and one warrant (exercise price $10.00, 6-month term), to raise $10M-$15M gross.
- Proceeds used for: $1.1M loan repayment to First Finance Ltd., $2M R&D for Orion/Stroke Recovery, $1M Orion pivotal trial prep, $4M device manufacturing, and working capital/merger expenses.
- Merger with Cortigent (pre-revenue neurotech firm) is conditioned on this financing; Cortigent has no revenue, net losses of $1.0M (H1 2026), $3.1M (FY2025), $2.2M (FY2024), and a going-concern qualification.
- Cortigent's Orion system completed a 6-subject early feasibility study in March 2025; pivotal trial expected to start late 2027, with potential commercial launch in 2030 — no guarantee of FDA approval.
- Selling stockholders are registering 2,496,162 shares (93.3% of pre-offering outstanding), creating massive overhang; post-merger pro forma shares outstanding range from 18.9M to 20.3M.
- CLRO has a $14M market cap, $75K cash as of June 30, 2026, and a $500K short-term note payable; pro forma cash at minimum offering is $7.7M, at maximum $12.4M.
Financial Impact
Offering raises $10M-$15M gross ($9.05M-$13.75M net). Cortigent has no revenue; net losses of $1.0M (H1 2026), $3.1M (FY2025), $2.2M (FY2024). Pro forma combined net loss for FY2025 is $41.8M, for H1 2026 is $14.5M.
Risk Factors
- Best-efforts offering may not close at minimum $10M threshold, killing the merger and leaving CLRO as a cash-poor shell.
- Cortigent's Orion pivotal trial may fail or be delayed; FDA approval is uncertain and years away.
- Massive dilution: pro forma shares increase 7-8x from current 2.68M to 18.9M-20.3M; warrants add further dilution at $10 strike.
- Selling stockholder overhang of 2.5M shares (93% of current float) will pressure the stock post-offering.
- Combined company has going-concern risk; Cortigent requires substantial additional capital beyond this offering to complete clinical trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001753926-26-001724 |
| Exhibit: ex44_4.htm | 0001753926-26-001724 |
| Exhibit: ex42_3.htm | 0001753926-26-001724 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $3.10 $1.92 | ▼ −38.06% | ▼ −37.05% | $4.97 (+60.32%) |
Oct 13, 2026 13d ago | 8-K | $3.76 $1.89 | ▲ +49.73% | ▲ +48.58% | $4.97 (−32.18%) |
Sep 4, 2026 7w ago | S-1/A | $5.01 $4.41 | ▲ +11.98% | ▲ +10.86% | $4.97 (+0.80%) |
Apr 13, 2026 28w ago | 8-K | $2.72 $3.25 | ▼ −19.49% | ▼ −18.09% | $4.97 (−82.72%) |
Apr 3, 2026 29w ago | 8-K | $3.30 $3.10 | ▲ +6.06% | ▲ +10.20% | $4.97 (−50.61%) |
Mar 5, 2026 33w ago | 8-K | $4.55 $4.41 | ▲ +3.08% | ▲ +1.55% | $4.97 (−9.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers